Program
Linagliptin
Also written as “BI 1356”, “linagliptin” and “Linagliptin/Metformin FDC”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus · Esophageal Neoplasms · Carcinoma, Non-Small-Cell Lung · Hypertension, led by 7 companies.
Drug pageLinagliptin: every studyMany companies study it; this page follows only the 89 they lead. All 129 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheim | 800 open or running | phase 4since Sep 21, 2011 | Mar 31, 2006 | none ahead |
| Dong Wha Pharmaceuticalits history only | 30 open or running | phase 1since Aug 6, 2014 | Aug 6, 2014 | none ahead |
| Profil Institut für Stoffwechselforschungits history only | 20 open or running | phase 4since Jul 11, 2013 | Jul 11, 2013 | none ahead |
| Genuine Research Center, Egyptits history only | 10 open or running | phase 1since Aug 3, 2016 | Aug 3, 2016 | none ahead |
| ikfe-CROits history only | 10 open or running | phase 3since Feb 11, 2015 | Feb 11, 2015 | none ahead |
| Marcus Borchertits history only | 10 open or running | phase 4since Feb 21, 2012 | Feb 21, 2012 | none ahead |
| Nabiqasim Industries (Pvt)its history only | 11 open or running | phase 4since Feb 19, 2025 | Feb 19, 2025 | none ahead |
Also a collaborator on its studies: Halozyme Therapeutics, BioLineRx, Eli Lilly, Eva Pharma, Ikfe and MLM Medical Labs.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Boehringer Ingelheim only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 19 studies since Aug 25, 2010.
- Mar 7, 20142 phase 1 studies in HealthyNCT02084082, NCT02084056
- Apr 22, 2014Phase 1 study in HealthyNCT02121509 · 74 enrolled · Germany
- Jun 24, 20144 phase 1 studies in HealthyNCT02173665, NCT02173652, NCT02173639 and 1 more
- Jul 1, 201421 phase 1 studiesNCT02180503, NCT02183532, NCT02183506 and 18 more
- Jul 4, 2014Phase 2 study in Diabetes Mellitus, Type 2NCT02183324 · 72 enrolled
- Aug 19, 20143 phase 1 studies in HealthyNCT02221414, NCT02221401, NCT02220647
- Sep 15, 2014Phase 4 study in Diabetes Mellitus, Type 2NCT02240680 · 302 enrolled · United States, Australia, Belgium and more
- May 21, 2015Phase 3 study in Diabetes Mellitus, Type 2NCT02453555 · 275 enrolled · Japan
- Apr 29, 2016Phase 1 study in HealthyNCT02758171 · 56 enrolled · Germany
- Jun 24, 20162 phase 1 studies in HealthyNCT02815644, NCT02821910
- Aug 30, 2016Phase 3 study in Diabetes Mellitus, Type 2NCT02897349 · 206 enrolled · China
- Aug 22, 2017Phase 1 study in HealthyNCT03259490 · 30 enrolled · Germany
- Feb 6, 2018Phase 3 study in Diabetes Mellitus, Type 2NCT03429543 · 175 enrolled · United States, Argentina, Brazil and more
- Aug 9, 2018Phase 1 study in HealthyNCT03629054 · 30 enrolled · Germany
TargetBeta
“A potent, orally bioavailable dihydropurinedione-based inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity”NCIt, by rule
“Dipeptidyl peptidase IV inhibitor”ChEMBL 37, by rule
Other programs on DPP4
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sitagliptinrule | Merck | phase 4 | 123 |
| gemigliptinrule | LG Chem | phase 4 | 30 |
| anagliptinrule | JW Pharmaceutical | phase 4 | 6 |
| Empagliflozin/Linagliptinrule | Humanis Saglık Anonim Sirketi | phase 1 | 2 |
| cofrogliptinrule | Haisco Pharmaceutical Group | no phase | 1 |
Studies
The newest 60 of 80 Boehringer Ingelheim leads. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03629054Healthy · Germany | 1 | Completed | Nov 5, 2018 | 30 |
| NCT03429543Diabetes Mellitus, Type 2 · United States, Argentina, Brazil and more | 3 | Completed | Oct 19, 2022 | 175 |
| NCT03259490Healthy · Germany | 1 | Completed | Nov 13, 2017 | 30 |
| NCT02897349Diabetes Mellitus, Type 2 · China | 3 | Completed | Jan 11, 2019 | 206 |
| NCT02821910Healthy · Germany | 1 | Completed | Oct 1, 2016 | 50 |
| NCT02815644Healthy · Japan | 1 | Completed | Oct 5, 2016 | 22 |
| NCT02758171Healthy · Germany | 1 | Completed | Jul 29, 2016 | 56 |
| NCT02453555Diabetes Mellitus, Type 2 · Japan | 3 | Completed | Aug 26, 2016 | 275 |
| NCT02240680Diabetes Mellitus, Type 2 · United States, Australia, Belgium and more | 4 | Completed | Apr 18, 2017 | 302 |
| NCT02221414Healthy | 1 | Completed | Mar 2010 | 95 |
| NCT02221401Healthy | 1 | Completed | Apr 2010 | 96 |
| NCT02220647Healthy | 1 | Completed | Apr 2010 | 96 |
| NCT02191228Renal Insufficiency | 1 | Completed | Feb 2010 | 51 |
| NCT02183636Healthy | 1 | Completed | Dec 2009 | 39 |
| NCT02183623Healthy | 1 | Completed | Oct 2005 | 20 |
| NCT02183610Healthy | 1 | Completed | Sep 2006 | 12 |
| NCT02183584Healthy | 1 | Completed | Oct 2009 | 16 |
| NCT02183532Healthy | 1 | Completed | Jul 2009 | 12 |
| NCT02183506Healthy | 1 | Completed | Dec 2005 | 16 |
| NCT02183493Healthy | 1 | Completed | Dec 2008 | 32 |
| NCT02183480Healthy | 1 | Completed | Sep 2009 | 12 |
| NCT02183467Healthy | 1 | Completed | Jun 2008 | 44 |
| NCT02183428Healthy | 1 | Completed | Jul 2008 | 20 |
| NCT02183415Diabetes Mellitus, Type 2 | 1 | Completed | Jan 2006 | 77 |
| NCT02183402Healthy | 1 | Completed | Sep 2008 | 20 |
| NCT02183389Healthy | 1 | Completed | Oct 2008 | 18 |
| NCT02183376Hepatic Insufficiency | 1 | Completed | Mar 2009 | 33 |
| NCT02183363Healthy | 1 | Completed | May 2007 | 24 |
| NCT02183350Diabetes Mellitus, Type 2 | 1 | Completed | Aug 2005 | 47 |
| NCT02183337Healthy | 1 | Completed | Apr 2007 | 20 |
| NCT02183324Diabetes Mellitus, Type 2 | 2 | Completed | Jun 2007 | 72 |
| NCT02183311Healthy | 1 | Completed | Oct 2006 | 56 |
| NCT02183298Healthy | 1 | Completed | Jul 2006 | 36 |
| NCT02180503Healthy | 1 | Completed | Oct 2005 | 24 |
| NCT02175394Healthy | 1 | Completed | Oct 2008 | 18 |
| NCT02173665Healthy | 1 | Completed | Dec 2004 | 64 |
| NCT02173652Healthy | 1 | Completed | Apr 2008 | 16 |
| NCT02173639Healthy | 1 | Completed | Jun 2009 | 20 |
| NCT02121509Healthy · Germany | 1 | Completed | Jul 2014 | 74 |
| NCT02084082Healthy · Germany | 1 | Completed | Jul 2014 | 68 |
| NCT02084056Healthy · Germany | 1 | Completed | Jul 2014 | 74 |
| NCT01947153Healthy · Russian Federation | 1 | Completed | Jan 2014 | 36 |
| NCT01897532Diabetes Mellitus, Type 2 · United States, Argentina, Brazil and more | 4 | Completed | Jan 18, 2018 | 6,991 |
| NCT01845077Healthy · United States | 1 | Completed | Aug 2013 | 72 |
| NCT01792518Diabetes Mellitus, Type 2 · United States, Canada, Denmark and more | 3 | Completed | Nov 2015 | 360 |
| NCT01708902Diabetes Mellitus, Type 2 · China, Malaysia, Philippines and more | 3 | Completed | Apr 2014 | 876 |
| NCT01703286Diabetes Mellitus, Type 2 · Germany | 1 | Completed | Jan 2014 | 42 |
| NCT01581931Healthy · Germany | 1 | Completed | Jun 2012 | 32 |
| NCT01540487Healthy · China | 1 | Completed | Jun 2012 | 48 |
| NCT01512979Diabetes Mellitus, Type 2 · United States, Canada, India and more | 4 | Completed | Apr 2013 | 316 |
| NCT01438814Diabetes Mellitus, Type 2 · Bangladesh, Belgium, Canada and more | 4 | Completed | Mar 2013 | 689 |
| NCT01342484Diabetes Mellitus, Type 2 · United States, Canada, France and more | 2 | Completed | Feb 2016 | 40 |
| NCT01276327Healthy · Germany | 1 | Completed | May 2011 | 64 |
| NCT01243424Diabetes Mellitus, Type 2 · United States, Argentina, Australia and more | 3 | Completed | Aug 21, 2018 | 6,103 |
| NCT01216397Healthy · Germany | 1 | Completed | Dec 2010 | 40 |
| NCT01215097Diabetes Mellitus, Type 2 · China, Malaysia, Philippines | 3 | Completed | Apr 2012 | 306 |
| NCT01214239Diabetes Mellitus, Type 2 · China, Malaysia, Philippines | 3 | Completed | May 2012 | 300 |
| NCT01204294Diabetes Mellitus, Type 2 · Japan | 3 | Completed | Jan 2012 | 574 |
| NCT01194830Diabetes Mellitus, Type 2 · United States | 3 | Completed | Oct 2011 | 234 |
| NCT01189201Healthy · Germany | 1 | Completed | Nov 2010 | 42 |
How it is read
Names in the registry
- “Linagliptin”, 35 entries
- “BI 1356”, 14 entries
- “linagliptin”, 10 entries
- “Linagliptin/Metformin FDC”, 4 entries
- “BI 1356 BS”, 3 entries
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 46 studies
- Diabetes Mellitus, 2 studies
- Esophageal Neoplasms, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
- Hypertension, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.